| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Andreas Jung | |
| Stefan C Müller | |||
| Alexander von Ruecker | |||
| Jörg Ellinger | |||
| Patrick J Bastian | |||
| Thomas C Stadler | |||
| P2860 | cites work | Multimarker circulating DNA assay for assessing blood of prostate cancer patients | Q83161613 |
| CpG island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer | Q83843096 | ||
| Mortality results from a randomized prostate-cancer screening trial | Q24601536 | ||
| Cancer statistics, 2009 | Q29547625 | ||
| Screening and prostate-cancer mortality in a randomized European study | Q29617485 | ||
| Rapid clearance of fetal DNA from maternal plasma | Q34388637 | ||
| Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats | Q34530414 | ||
| Neoplastic characteristics of the DNA found in the plasma of cancer patients | Q34543792 | ||
| DNA integrity assay: a plasma-based screening tool for the detection of prostate cancer | Q34555788 | ||
| Prediction of breast tumor progression by integrity of free circulating DNA in serum. | Q34565015 | ||
| CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer | Q37243155 | ||
| Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer | Q39635993 | ||
| The role of cell-free DNA size distribution in the management of prostate cancer | Q39759469 | ||
| Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer. | Q39766437 | ||
| Comparison of genetic alterations detected in circulating microsatellite DNA in blood plasma samples of patients with prostate cancer and benign prostatic hyperplasia | Q39774957 | ||
| Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer. | Q39838615 | ||
| Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer | Q40178819 | ||
| Circulating nucleosomes and response to chemotherapy: an in vitro, in vivo and clinical study on cervical cancer patients | Q42438397 | ||
| Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer | Q43894326 | ||
| Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. | Q44022435 | ||
| Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer | Q44244665 | ||
| Methylation-specific sequencing of GSTP1 gene promoter in circulating/extracellular DNA from blood and urine of healthy donors and prostate cancer patients | Q45122355 | ||
| Deoxyribonuclease activity and circulating DNA concentration in blood plasma of patients with prostate tumors. | Q45939035 | ||
| Cell-free circulating DNA: diagnostic value in patients with testicular germ cell cancer | Q46245638 | ||
| Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy | Q46522673 | ||
| Effects of preanalytical factors on the molecular size of cell-free DNA in blood | Q47391984 | ||
| CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. | Q53324496 | ||
| Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma. | Q53571983 | ||
| Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer. | Q54536146 | ||
| Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence after prostatectomy. | Q54537328 | ||
| Apoptotic DNA fragments in serum of patients with muscle invasive bladder cancer: a prognostic entity. | Q54542903 | ||
| Identification of loss of heterozygosity on circulating free DNA in peripheral blood of prostate cancer patients: potential and technical improvements. | Q54546139 | ||
| Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer. | Q54564042 | ||
| Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients. | Q54622658 | ||
| Role of cell-free plasma DNA as a diagnostic marker for prostate cancer. | Q54710249 | ||
| Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. | Q54769141 | ||
| Prospective Study of Quantitation of Plasma DNA Levels in the Diagnosis of Malignant versus Benign Prostate Disease | Q58211955 | ||
| Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease | Q72694781 | ||
| Cell-free DNA: measurement in various carcinomas and establishment of normal reference range | Q74179991 | ||
| Higher amount of free circulating DNA in serum than in plasma is not mainly caused by contaminated extraneous DNA during separation | Q79362886 | ||
| Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance | Q79456929 | ||
| CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer | Q79838607 | ||
| Cell-free DNA and RNA in plasma as a new molecular marker for prostate cancer | Q80876299 | ||
| Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators | Q80975961 | ||
| Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy | Q81310325 | ||
| P433 | issue | 2 | |
| P921 | main subject | prostate cancer | Q181257 |
| diagnosis | Q16644043 | ||
| P304 | page(s) | 124-129 | |
| P577 | publication date | 2009-09-17 | |
| P1433 | published in | Urologic Oncology | Q2113446 |
| P1476 | title | The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer | |
| P478 | volume | 29 |
| Q57166936 | Circulating Tumour DNA in Muscle-Invasive Bladder Cancer |
| Q38191574 | Circulating and stool nucleic acid analysis for colorectal cancer diagnosis. |
| Q35603660 | Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone. |
| Q28533510 | Circulating mitochondrial DNA as biomarker linking environmental chemical exposure to early preclinical lesions elevation of mtDNA in human serum after exposure to carcinogenic halo-alkane-based pesticides |
| Q38165244 | Circulating nucleic acids as biomarkers of prostate cancer. |
| Q38211361 | Circulating tumour cells-monitoring treatment response in prostate cancer |
| Q35125657 | Circulating tumour markers can define patients with normal colons, benign polyps, and cancers |
| Q38584370 | Current biomarkers for diagnosing of prostate cancer |
| Q33838513 | Epigenetic Signature: A New Player as Predictor of Clinically Significant Prostate Cancer (PCa) in Patients on Active Surveillance (AS) |
| Q38365422 | Epigenetic biomarkers in the blood of patients with urological malignancies |
| Q47563953 | Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients |
| Q40985522 | Methylation pattern analysis in prostate cancer tissue: identification of biomarkers using an MS-MLPA approach. |
| Q38216129 | Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies. |
| Q33395491 | Plasma circulating nucleic acids levels increase according to the morbidity of Plasmodium vivax malaria |
| Q57110507 | Predictive value of circulating cell-free DNA in the survival of breast cancer patients: A systemic review and meta-analysis |
| Q38160475 | Role of biochemical markers in testicular cancer: diagnosis, staging, and surveillance |
| Q54578238 | Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker. |
| Q37507351 | The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC. |
| Q35854622 | Urinary Biomarkers for Prostate Cancer |
| Q28083261 | Using circulating tumor cells to inform on prostate cancer biology and clinical utility |
| Q26768470 | When Prostate Cancer Circulates in the Bloodstream |
| Q85779116 | [Detection of cell-free lncRNA in serum of cancer patients] |
Search more.